Neuphoria Therapeutics Inc.

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NEUP and other ETFs, options, and stocks.

About NEUP

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. 

CEO
Spyridon Papapetropoulos
CEOSpyridon Papapetropoulos
Employees
24
Employees24
Headquarters
Burlington, Massachusetts
HeadquartersBurlington, Massachusetts
Founded
1996
Founded1996
Employees
24
Employees24

NEUP Key Statistics

Market cap
8.86M
Market cap8.86M
Price-Earnings ratio
-80.13
Price-Earnings ratio-80.13
Dividend yield
—
Dividend yield—
Average volume
15.55K
Average volume15.55K
High today
$5.20
High today$5.20
Low today
$5.04
Low today$5.04
Open price
$5.20
Open price$5.20
Volume
3.47K
Volume3.47K
52 Week high
$15.24
52 Week high$15.24
52 Week low
$2.12
52 Week low$2.12
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.